Novartis (NYSE: NVS) is paying $1.1 billion upfront to buy Myricx Bio, a London-based biotech with its U.S. presence based in ...

In South San Francisco, Genentech showed that recombinant DNA technology could transform medicine and create therapies once ...

The company recently wowed investors with clinical trial results.

David Craig’s operating manual for building biotech companies in today’s market is now available in hardcover and as an ...

Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...

Seven life sciences companies cut at least 346 jobs in Massachusetts between April and June, with some of the layoffs tied to ...

Psychedelic therapy developer Definium Therapeutics convinced a federal judge in Delaware on Wednesday to dismiss a lawsuit ...

By Karen Roman Imviva Biotech said it has FDA authorization for its Investigational Device Exemption application to use ...

June 29 (Reuters) - Ipsen will buy U.S.-based Kartos Therapeutics for $450 million to expand its oncology pipeline with a ...

A French drugmaker just bet up to $1.75 billion on a cancer drug that's only been tested on 19 patients — why?

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.